Psoriasis of the nails L40.8
Synonym(s)
Definition
This section has been translated automatically.
A common manifestation of psoriasis that occurs on one or more nails (see “Nail” below) and, particularly in severe cases, places a significant psychological and physical-motor burden on the patient, with varying degrees of severity. Up to 80% of patients with associated psoriatic arthritis are affected by “nail changes” at the time of diagnosis. The condition is likely the most common nail disorder after onychomycosis.
Psoriatic onychopathy is often associated with a severe form of psoriasis (early onset, high risk of psoriatic arthritis) and can lead to significant functional limitations and a reduced quality of life. Notably, fingernails are more frequently affected than toenails.
In general, nail psoriasis is considered difficult to treat, due to the fact that the nail plate is a high-density, hydrophilic “keratin nail.” This hinders the penetration of topical medications, often rendering them ineffective. Furthermore, the injections (e.g., triamcinolone injections) previously administered near the matrix or the nail bed are extremely painful and not without complications.
Determining the indication for systemic treatment poses a major medical challenge.
Classification
This section has been translated automatically.
Broadly speaking, psoriatic nail dystrophies can be explained by pathological changes
- in the proximal nail matrix
- of the distal nail matrix
- resulting from complex pathologies of the nail matrix and nail fold
Psoriatic pathologies of the proximal nail matrix
- Pitted nails (in about 75% of people with psoriasis)
- Lacunar nail plate defects (corresponding to oversized pitting)
- Thickening, structural changes, and discoloration of the nail plate (in 50% of people with psoriasis)
- Transverse ridges
- Longitudinal ridges
- Rasp-like pattern
Psoriatic pathologies of the distal nail matrix
- Oil spot (in 30% of cases, discoloration due to psoriatic parakeratosis of the nail bed; there is no direct connection to the free edge of the nail)
- Distal onycholysis (in 46% of cases due to subungual hyperkeratosis)
- Tenderness of the nail upon pressure, often in combination with oil spot formation (50% of affected individuals)
- Splinter hemorrhage (tiny, elongated hemorrhages under the nail plate)
- Nail bed pustulosis (formation of sterile subungual pustules in the area of the proximal and/or distal nail matrix)
Complex pathologies of the nail matrix and nail fold involving multiple compartments of the nail organ (combined occurrence of pitting, nail ridging, onychogryphosis, psoriatic pustulosis, synechiae, and anonychia as the final scarring stage)
- Psoriatic onychogryposis (paradoxical nail growth)
- Psoriatic crumb nail (severe form of psoriatic onychodystrophy with impaired longitudinal growth)
- Psoriatic anonychia with synechiae of the nail bed and nail fold, as the final stage of complex psoriatic nail dystrophy
You might also be interested in
Occurrence/Epidemiology
This section has been translated automatically.
m>w;Psoriasis is the skin condition that most commonly affects the nails and is likely the most common nail disorder after onychomycosis.
Nail psoriasis occurs in approximately 40%–50% (figures vary in the literature/Salomon JC et al. 2003; Armesto S et al. 2011; Rachakonda TD et al. 2014) of all psoriasis patients, or in 70–80% of all patients with psoriatic arthritis (see below: psoriatic arthropathy) (Canal-García E et al. 2022; Augustin M et al. 2010).
In most studies, the prevalence of nail involvement is assessed as part of studies on cutaneous psoriasis. There is a positive correlation between the presence of nail psoriasis, the duration of psoriasis, and between the severity of nail involvement and the severity of skin and joint lesions. The anatomical and physiological connections between the extensor tendon insertion and the nail apparatus are a possible reason (presence of enthesitis) for the close association between nail and joint diseases. The prevalence of isolated nail involvement (psoriatic nail involvement without psoriasis) is reported to be as high as 6% (Rigopoulos D et al. 2014).
Nail psoriasis in childhood has a prevalence of 17–38% and is associated with a severe form of psoriasis (Al-Mutairi N et al. 2007; Augustin M et al. 2010; Mercy K et al. 2013).
Nail psoriasis is characterized by various clinical presentations that can occur in isolation or in combination on individual or multiple fingernails or toenails.
In a larger cohort,
- 75% of patients with psoriasis had pitted nails (not specific to psoriasis; also seen in chronic hand dermatitis)
- thickening and a white-yellowish discoloration of the nail plate in 50%
- 46% had (distal) onycholysis
- 30% had yellowish-brownish discoloration due to parakeratotic thickening of the nail plate (oil spot)
- 50% of those affected complained of pain (mostly pressure pain).
Furthermore:
- Splinter hemorrhages (tiny, elongated hemorrhages beneath the nail plate)
- Subungual hyperkeratosis (caused by psoriatic lesions in the distal nail bed and/or hyponychium)
- Paradoxical nail growth: increased thickness of the nail at the expense of longitudinal growth
- Psoriatic paronychia: inflammatory involvement of the paronychium with varying degrees of swelling and scaling. Often accompanied by thickening or even loss of the eponychium
- Psoriatic crumb nail, representing the most severe form of psoriatic onychodystrophy
- Pustular nail psoriasis with the formation of sterile pustules. Prone to scarring atrophy. Severe form = acrodermatitis continua suppurativa
Etiopathogenesis
This section has been translated automatically.
The etiopathogenesis of psoriatic nail involvement is unclear so far. Some authors discuss variations in the IL1RN gene, a regulator of the proinflammatory activity of IL-1A. The encoded cytokine has been shown to cause nail changes and therefore may be responsible for psoriatic nail pathology (Julià A et al. 2012. In psoriasis, several psoriasis susceptibility alleles are known, with HLA Cw0602 being the best studied (Dand N et al. 2020). However, nail involvement is less common in this haplotype (Ogawa K et al. 2020).
Manifestation
This section has been translated automatically.
In general, the nails of the hands are affected significantly more often than the toes. The fourth finger and the first toe are preferred (Brazzelli V et al. 2012). Clinical findings also differ between fingernails and toenails. Typically, fingernails are affected by mottling, whereas nail hyperkeratosis and onycholysis are more common on toenails (Brazzelli V et al. 2012).
Clinic
This section has been translated automatically.
Nail psoriasis is characterized by various clinical manifestations that may occur in isolation or in combination on single or multiple fingernails or toenails.
In a larger cohort
- spotted nails in 75% of psoriatic patients (not specific to psoriasis, also seen in chronic hand dermatitis)
- in 50% a thickening and white-yellowish discoloration of the nail plate
- in 46% (distal) onycholysis
- in 30% yellowish-brown discoloration due to parakeratotic keratinization of the nail plate (oil stain)
- 50% of the affected complained of pain (mostly pressure pain).
Furthermore:
- Splinter hemorrhages (smallest elongated hemorrhages below the nail plate)
- Subungual hyperkeratosis (caused by psoriatic areas in the distal nail bed and/or the hyponychium).
Transverse grooves/longitudinal grooves: Transverse grooves of the nail plate occur in the wake of chronic, and psoriatic involvement of the proximal nail matrix. Not infrequently, densely staggered psoriatic transverse grooves are accompanied by shingle-like surface exfoliation of the nail plate. Transverse grooves are not infrequently combined with dehiscence of the nail folds and nail plate. In the area of the proximal nail fold, this leads to a loss of the cuticle, which means that a protective function of the nail organ is lost.
Longitudinal grooves: Longitudinal grooves are usually rather discrete in psoriasis. They have no diagnostic value typical for psoriasis, because they are also frequently found in ageing nails.
-
Rubbed iron nail(trachyonychia): A rubbing iron-like nail surface is usually observed as a result of severe generalized psoriasis. The rubbing iron nail - trachyonychia - is the result of diffusely disturbed function of the proximal nail matrix. Trachyonychia should be classified as a nonspecific nail dystrophy, since it can also be observed in other generalized skin diseases (e.g., erythroderma/ichen planus).
Psoriatic paronychia: inflammatory involvement of the paronychium with varying degrees of swelling and scaling. Frequent thickening or even loss of the cuticle (eponychium).
Psoriatic onychgryposis: Onychogryphalic nails are an indication of a severe complex disorder especially of the distal and proximal nail matrix. Due to chronic psoriatic inflammation, there is a disturbance of horizontal-distal growth. This finding is not psoriasis-specific and can also be observed in other digital pathologies of the skin (e.g. in erythroderma), as well as in recurrent trauma of the nail matrix (e.g. in soccer players).
- Psoriatic crumb nail, as a maximum form of psoriatic onychodystrophy.
- Pustular nail psoriasis with formation of sterile pustules. Prone to scarring atrophy. Pustulosis of the nail bed can lead to complete anonychia. Acrodermatitis continua suppurativa may be considered the maximal form.
Comorbidities and associated factors
- Psoriatic arthritis: Psoriatic arthritis is the most common comorbidity in psoriasis, occurring (clinically) in 5-42% of patients (McGonagle D et al 2009). Approximately 80-90% of patients with psoriatic arthritis develop nail involvement (Lai TL et al 2016). Patients with psoriatic arthritis are significantly more likely to develop psoriatic onychopathy than those with only skin involvement (Lai TL et al. 2016). Thus, it is also postulated that nail involvement is a predictor of enthesopathy. The clinical association between enthesopathy and onychopathy is explained by the anatomical proximity of extensor tendon of distal phalanx and nail matrix(Tan AL et al. 2007; Tan AL et al. 2007; Wilson FC et al. 2009; Williamson L et al. 2004; Kaeley GS et al. 2021).
- Onychomycosis: The clinical differential diagnosis between nail psoriasis and onychomycosis is often difficult. Moreover, coexistence of the two diseases occurs in 30% of patients with nail psoriasis (Zisova L et al. 2012; Klaassen KMG et al. 2013). It is postulated that morphological changes in psoriatic nails are predisposing factors for onychomycosis and that onychomycosis may act as a Köbner phenomenon for the development of psoriatic onychopathy (Klaassen KMG et al. 2013). The consequence of this frequent coexistence of onychomycosis and nail psoriasis is that cultural fungal exclusion is recommended before starting treatment, especially when immunosuppressive drugs are needed (Kaul S et al. 2018). Meanwhile, some centers have a rapid diagnostic test consisting of an immunochromatographic assay that can detect Trichophyton antigens in nail samples and provide immediate results with sufficient quality (Paugam A et al. 2021).
- Smoking: Apparently, smoking is an independent risk factor for psoriasis (Armstrong AW et al.2011). Recently, it has been shown that smoking psoriatic patients are more likely to develop psoriatic onychopathy than non-smokers (Temiz SA 2020).
Histology
This section has been translated automatically.
The classic histologic features of nail psoriasis overlap with the findings of cutaneous psoriasis and include: mild to moderate hyperkeratosis, focal parakeratosis, psoriasiform papillomatosis, dilated and tortuous capillaries in the papillary dermis, and neutrophilic infiltrates (Grover C et al 2005). In addition, there may be loss of stratum granulare in the hyponychium and hypergranulosis in the nail matrix as well as in the nail bed (Grover C et al 2005). The matrix epithelium in the area of a stippling usually shows mild spongiosis with exocytosis of lymphocytes and neutrophils.
Diagnosis
This section has been translated automatically.
Differential diagnosis
This section has been translated automatically.
Tinea unguium (most important differential diagnosis!): Toenails are more frequently affected, slow nail growth, rarely pits, frequent onycholysis, microscopic detection of spores and mycelia (careful sampling technique); positive culture!
Onychogrypose (common in old age): Highly domed, thickened, often discolored, claw-like, hard nail plate. Formation of large, malformed nails that have grown in the "wrong direction". The nail matrix is hard and not crumbly.
Lichen planus: Mostly thinned (!) nail plates with longitudinal surface distortions(trachyonychia) and numerous spots. Complete (atrophic) destruction of the nail plate is possible.
Eczema nails: Not clearly assigned term for nail changes in chronic hand eczema. In this respect, the clinical symptoms are of different types: often irregular nail surface with grooves, furrows, spotting, splitting, thickening of the nail plate, onycholysis and color changes. No psoriatic stigmata of the skin.
Onycholysis semilunaris: Crescent-shaped incomplete onycholysis with detachment of the nail plate from the free edge. No other psoriatic stigmata.
Leukonychia (differential diagnosis see there): Polyetiologic symptom with punctate, transverse, longitudinal, or homogeneous total whitening of the nail plate (leading symptom: nail, white), which may involve one or more nails.
Yellow-nail syndrome: Thickened, yellow discolored nails throughout the nail area, slow or no growth, scleronychia with peripheral onset onycholysis.
Twenty-nail dystrophy: Often present at birth or developing in the first few months of life. Usually affects all nails. Nail dystrophies vary, mostly thickened, not crumbly, no spots or oil stains, no integumentary psoriasis.
Complication(s)(associated diseases
This section has been translated automatically.
About half of patients with nail psoriasis report limitations in their daily functions in everyday life, depending on the extent of the changes.
Around 50% of those affected report pain.
General therapy
This section has been translated automatically.
The treatment of nail psoriasis is extremely difficult and lengthy and thus requires a lot of patience. Patients unfortunately have to learn to live with the versch. Unfortunately, patients have to learn to live with the various forms of psoriatic onychodystrophy over a longer period of time. The current therapeutic arsenal of systemic therapeutics is very broad. From this broad assortment, the individual therapeutic treatment approach has to be chosen considering the clinical constellation. It includes both "wait and see" and, in severe cases, the use of systemic therapeutics. Special therapeutic consideration is required for psoriatic minus variants with solitary psoriatic onychopathy in which the local findings have led to considerable functional and psychological problems.
External therapy promises success only in milder forms. The following general rules of conduct should be observed:
- Avoid provocation factors (aggressive manicure or pedicure, manipulation of the cuticle).
- Cut nails short, especially in patients who are confronted with manual activities at work/at home/hobby.
- Before cutting, wash and grease nails (e.g. Linola grease ointment) to reduce splintering.
- If necessary, cut brittle nails only after a lukewarm oil or tar bath (Linola Fat Oil Bath, Balneum Hermal Oil Bath).
- Have transverse grooves or thickened nails milled by experienced medical chiropodists.
- Wear light, wide shoes that do not press on affected, deformed toenails.
- Artificial fingernails as an optical embellishment are possible.
- In case of psoriatic "crumb nails" occlusive treatment with 40% urea paste (see below urea (overview) soften for 10-14 days and have it milled off by a specialist.
External therapy
This section has been translated automatically.
There are only a few high-quality studies that evaluate and compare the various topical treatments for nail psoriasis. In general, products with a higher fat content (creams or ointments) applied under occlusion show better results than non-occlusive therapy. For nail bed involvement, treatment should be applied as close to the nail bed as possible after the onycholytic nail has been trimmed and “mild” subungual curettage has been performed (Jiaravuthisan MM et al. 2007). Various therapeutic options are available.
Topical corticosteroids: There is currently no consensus on a standard treatment regimen. In clinical practice, however, highly potent corticosteroids are frequently used, often under occlusion and over long periods of time. Caution is advised with long-term use due to the risk of skin atrophy (Kole L et al. 2014; Canal-García E et al. 2022). Alternatively: Try sertaconazole nail patches (Zalain® nail patches; cut to fit the nail and change once a week).
- Alternatively: Vitamin D derivatives (calcitriol, tacalcitol, calcipotriol): These topical agents are effective as monotherapy or in combination with topical corticosteroids (clobetasol or betamethasone). They appear to be more effective for psoriatic changes in the nail bed than for matrix-induced changes (Canal-García E et al. 2022; Rigopoulos D et al. 2022). For milder forms, try calcipotriol solution or ointment (e.g., Daivonex, Psorcutan solution) once daily, preferably in the evening, using occlusive dressings (finger cots, gloves) if possible, for at least 4–6 months.
- Alternative: Calcineurin inhibitors (tacrolimus): In one study, they were effective for both matrix and nail bed manifestations (De Simone C et al. 2013).
- Alternative: Tazarotene: Topical treatment with 0.1% tazarotene (cream/gel). Several positive study results (12–24 weeks of therapy) are available for this treatment (Rigopoulos D et al. 2007). This procedure appears to be effective when applied topically and occlusively. Its use may be limited by the frequent occurrence of erythema, scaling, irritation, and paronychia (Fischer-Levancini C et al. 2012; Canal-García E et al. 2022).
- Alternatively (for psoriatic onychogryphosis): Application of a 15% urea varnish (Onypso®). Apply once daily to the affected nails over a period of >6 months.
- Alternatively: For more severe forms, the topical application of 1% 5-fluorouracil or a solution containing 1% 5-fluorouracil plus salicylic acid or urea is recommended ( off-label use). Apply the solution once daily, followed by an occlusive dressing. Possible side effects include redness, itching, and a painful burning sensation. Electrotherapy: Interferential current therapy has also been reported to be effective for nail psoriasis (NEMECTRON; IONTO-COMED).
Intralesional corticosteroids: This treatment method is the only one yielding acceptable results. A depot should be placed medially and laterally below the matrix and beneath the nail plate. The corticosteroid should be administered using a 28–30G needle. It is advisable to use an analgesic technique in the area to avoid pain during and after the procedure (the most significant adverse effect). The most commonly used regimen involves injecting approximately 0.4 ml of triamcinolone acetonide at a concentration of 10 mg/ml. (Canal-García E et al. 2022; Abell et al. 1973). This is a highly painful procedure; nerve block anesthesia according to Oberst is required. If necessary, the procedure may be repeated every 2–4 months. Several studies have demonstrated significant success with this therapy (evidence level C).
Internal therapy
This section has been translated automatically.
General Recommendations: In recent years, the treatment of skin and nail psoriasis has made progress with the development of new medications that provide long-lasting efficacy (Pasch MC 2016). The treatment approach should be tailored individually based on the number of affected nails, the presence of associated skin and joint lesions, other comorbidities, the degree of impairment to quality of life, etc. Systemic treatments are the treatment of choice for patients with multiple affected nails or when nail psoriasis is accompanied by skin or joint manifestations. There are only a few randomized clinical trials that demonstrate clear positive clinical effects.
- Retinoids (acitretin): Retinoids have moderate efficacy, with NAPSI improvements of 40–50%. They are used at lower doses than for cutaneous psoriasis (0.2–0.3 mg/kg/day). Their mechanism of action is slow, but they are medications that can be used for years. The most common adverse effects are well-known ones such as cheilitis and skin desquamation (Canal-García E et al. 2022; Ricceri F et al. 2013).
- Methotrexate: Appears to be most useful for nail psoriasis. However, the efficacy achieved is only moderately good, with an improvement in NAPSI scores of 40–50%. The doses used are the same as for cutaneous psoriasis. Compared to treatments with biologics, efficacy is generally lower (Reich K et al. 2011).
- CyclosporineA: Cyclosporine A is effective for both nail bed and nail matrix onychopathy. Cyclosporine has proven effective as monotherapy but is increasingly used in combination with calcipotriol. Its use is limited to approximately 12 months due to the risk of kidney damage (Canal-García E et al. 2022).
- Apremilast: In clinical approval trials, the drug demonstrated improvements in both matrix and nail-bed psoriasis, with NAPSI changes of 60% after 52 weeks (Papp K et al. 2015; Lanna C et al. 2020).
Biologics: With most biologic drugs, the response in nail pathologies occurs significantly more slowly than in skin lesions and is generally evident starting at week 12. In general, fingernails improve earlier than toenails (due to faster growth). The following medications have been studied for their efficacy in nail psoriasis:
- Infliximab: Several studies have demonstrated the efficacy of infliximab on nail bed and nail matrix manifestations. Patients with severe psoriasis experienced faster and more extensive improvement than those with mild psoriasis. In addition, quality-of-life scores improved under infliximab treatment (Reich K et al. 2010; Canal-García E et al. 2022)
- Adalimumab: Several studies, including clinical trials and population-based cohorts, have investigated the efficacy of adalimumab in nail psoriasis and generally shown good results (NAPSI improvements ranging from 55% to 95%). This improvement was independent of prior treatment with infliximab or etanercept (Canal-García E et al. 2022; Thaçi, D et al. 2015).
- Etanercept: Several observational studies have demonstrated NAPSI improvements ranging from 50–90% (Luger TA et al. 2009).
- Ustekinumab: Ustekinumab has proven effective for lesions in the nail bed and nail matrix, with NAPSI improvements ranging from 57–97%. At the same time, it improved the quality of life of treated patients (Rigopoulos D et al. 2011; Patsatsi A et al. 2013).
- Secukinumab: The 2.5-year results show a sustained NAPSI improvement of approximately 70% and an improvement in quality of life (K. Reich et al. (2021).
- Ixekizumab: Several studies have demonstrated its efficacy with good response rates (NAPSI 100 improvement) of up to 55% (Van de Kerkhof P et al. 2017)
- Brodalumab: Several studies, including randomized clinical trials, have demonstrated the efficacy of this drug in nail psoriasis (Elewski B et al. (2020).
- Guselkumab: Guselkumab has been available for the treatment of cutaneous psoriasis since 2019. In the approval studies, this drug demonstrated improvements in the NAPSI score compared to placebo after 16 weeks (Foley P et al. 2018).
- Risankizumab: In clinical trials, risankizumab demonstrated statistically significant improvements in the NAPSI score compared with placebo at weeks 16 and 52 (Gordon KB et al. 2018).
- In summary, a network meta-analysis evaluated the results of 7 comparative clinical trials involving 6 biologic drugs:The analysis included patients with concurrent moderate psoriasis and nail psoriasis. The primary endpoint was the complete resolution of nail lesions (NAPSI, mNAPSI, or PGA of 0) at weeks 24–26. The probability of a complete response was highest with ixekizumab (46.5%), followed by brodalumab (37%), adalimumab (28.3%), guselkumab ( 27.7%), ustekinumab (20.8%), and infliximab (0.8%) (Reich K et al. 2021). In cases of concomitant psoriatic arthritis, combination therapy with methotrexate may be considered.
Note(s)
This section has been translated automatically.
Psoriatic onychodystrophy is often seen as a "secondary problem" to be neglected. In this context, the clinical problem can reach a serious clinical magnitude due to stigmatization, functional limitations of daily activities, secondary infections and pain.
With regard to isolated nail psoriasis, the risk-benefit profile of internal therapy must be considered!
For objectification and follow-up of nail involvement the "Nail Psoriasis Severity Index ( NAPSI) has been developed. Alternative scores are: NPQ10 (Nail Psoriasis Quality of Life - to assess the impact of nail psoriasis on the quality of life of the individual) and NAPPA (Nail Assessment in Psoriasis and Psoriasic Arthritis). Other scales used primarily in clinical trials include the modified NAPSI (mNAPSI) (Rich P et al. 2003; Cassell SE et al. 2007; Hudgens S et al. 2021).
Clinically important is the observation, confirmed in a multivariate regression analysis, that nail infestation must be considered a negative prognostic factor (Bardazzi F et al. 2017).
Literature
This section has been translated automatically.
- Abell e et al (1973) Intradermal triamcinolone treatment of nail dystrophies. Br J Dermatol 89: 191-197
- Al-Mutairi N et al (2007) Nail changes in childhood psoriasis: a study from Kuwait. Pediatr Dermatol 24: 7-10
- Armesto S et al (2011) Nail psoriasis in individuals with psoriasis vulgaris: a study of 661 patients. Actas Dermosifiliogr102: 365-372
- Armstrong AW et al.(2011) Smoking and pathogenesis of psoriasis: a review of oxidative, inflammatory and genetic mechanisms. Br J Dermatol 165: 1162-1168.
- Augustin M et al. (2010) Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol 163: 580-585
- Baran R et al (2003) A text atlas of nail disorders: techniques in investigation and diagnosis. 3 rd ed CRC Press;
- Bardazzi F et al (2017) Nail involvement as a negative prognostic factor in biological therapy for psoriasis: a retrospective study. J Eur Acad Dermatol Venereol 31:843-846.
- Bianchi L et al.(2005) Remission and time of resolution of nail psoriasis during infliximab therapy.J Am Acad Dermatol 52:736-737.
- Brazzelli V et al. (2012) Prevalence, severity and clinical features of psoriasis in fingernails and toenails in adult patients: Italian experience. J Eur Acad Dermatol Venereol 26:1354-1359.
- Canal-García E et al (2022) Nail psoriasis. Actas Dermosifiliogr 113:481-490.
- Cassell SE et al (2007) The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 34: 123-129.
- Dand N et al (2020) Psoriasis and genetics. Acta Derm Venereol 100: 55-65.
- De Simone C et al (2013) Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled open-label study J Eur Acad Dermatol Venereol 27: 1003-1006.
- Elewski B et al (2020) Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials. J Dermatolog Treat (2020): 1-5.
- Elewski BE et al (2018) Adalimumab for nail psoriasis: efficacy and safety from the first 26 weeks of aphase 3, randomized, placebo-controlled trial. J Am Acad Dermatol 78:90-99.
- Fischer-Levancini C et al. (2012) Nail psoriasis: treatment with tazarotene 0.1% hydrophilic ointment. Actas Dermosifiliogr 103: 725-728.
- Foley P et al (2018) Efficacy of guselkumab Compared With adalimumab and placebo for psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Dermatol., 154: 676-683
- Fuchs G (2011) Nail psoriasis. Compendium Dermatology 7:15
- Gordon KB et al (2018) Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 392: 650-661
- Grover C et al (2005) Diagnosis of nail psoriasis: importance of biopsy and histopathology. Br J Dermatol 153: 1153-1158.
- Hudgens S et al (2021) Development and validation of the Physician's Global Assessment of Fingernail Psoriasis. J Eur Acad Dermatol Venereol 35: 2324-2330.
- Idrees S et al (2012) Frequency of nail changes in patients with psoriasis reporting to PNS, Shifa Naval Hospital Karachi. J Pak Assoc Dermatol 22: 315-319.
- Jiaravuthisan MM et al (2007) Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 57: 1-27
- Julià A et al. (2012) Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes. Hum Mol Genet: 4549-4557
- K. Reich et al. (2021) Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study. Br J Dermatol 184: 425-436.
- Kaeley GS et al (2021) Nail psoriasis: diagnosis, assessment treatment options, and unmet clinical needs. J Rheumatol 48: 1208-1220.
- Kaul S et al (2018) Clinical and histological spectrum of nail psoriasis: A cross-sectional study J Cutan Pathol 45: 824-830.
- Klaassen KMG et al (2013) Nail psoriasis: a questionnaire-based survey. Br J Dermatol169: 314-319.
- Kole L et al (2014) A randomized, double-blinded trial evaluating the efficacy and tolerability of vectical ointment (calcitriol 3 mcg/g ointment) when compared to betamethasone diproprionate ointment (64 mg/g) in patients with nail psoriasis. J Drugs Dermatol 13: 912-915.
- Lai TL et al (2016) Psoriatic nail involvement and its relationship with distal interphalangeal joint disease Clin Rheumatol (2016): 2031-2037.
- Lanna C et al (2020) Apremilast as a target therapy for nail psoriasis: a real-life observational study proving its efficacy in restoring the nail unit. J Dermatolog Treat. (2020): 1-5
- Luger TA et al. (2009) Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol 23: 896-904.
- Maranda EL et al (2016) Laser and light therapies for the treatment of nail psoriasis. J Eur Acad Dermatol Venereol 30: 1278-1284.
- McGonagle D et al (2009) The pathogenesis of psoriatic arthritis and associated nail disease: not autoimmune after all? Curr Opin Rheumatol 21: 340-347.
- Mercy K et al. (2013) Clinical manifestations of pediatric psoriasis: results of a multicenter study in the United States. Pediatr Dermatol, 30: 424-428.
- Ogawa K et al (2020) The current landscape of psoriasis genetics in 2020. J Dermatol Sci 99: 2-8.
- Papp K et al (2015) Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol 73. 37-49.
- Pasch MC (2016) Nail psoriasis: a review of treatment options.
- Patsatsi A et al (2013) Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study. J Dermatolog Treat 24: 96-100
- Paugam A et al (2022) Dermatophytic onychia: effectiveness of rapid immunochromatographic diagnostic testing directly on samples compared to culture. Ann Dermatol Venereol) 149:108-111.
- Reich K (2009) A treatment approach in patients with nail psoriasis. JEADV 23 (Suppl):15-21.
- Reich K et al (2010) Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial. Dermatology 221: 172-178
- Reich K et al (2011) A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 365: 1586-1596
- Reich K et al (2021) Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis J Dermatolog Treat (2021): 1-9.
- Ricceri F et al (2013) Treatment of severe nail psoriasis with acitretin: an impressive therapeutic result. Dermatol Ther 26: 77-78
- Rich P et al (2003) Nail psoriasis severity index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 49: 206-212.
- Rich P et al (2008) Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol 58: 224-231
- Rigopoulos D et al.(2007) Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate0.05% cream: a double-blind study. Acta Derm Venereol. 2007;87(2):167-8.
- Rigopoulos D et al. (2011) Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study. Dermatology 223: 325-329
- Rigopoulos D et al (2014) editors. Nail psoriasis: from A to Z. London: Springer
- Rigopoulos D et al. (2022) Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Derm Venereol 82: 140
- Singh SK (2013) Finger nail pitting in psoriasis and its relation with different variables. Indian J Dermatol. 58: 310-312.
- Tan AL et al. (2007) The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis--a high-resolution MRI and histological study. Rheumatology (Oxford) 46: 253-256.
- Temiz SA (2020) The effect of smoking on the psoriasis: Is it related to nail involvement? Dermatol Ther 33: 3630-3633
- Thaçi, D et al. (2015) Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study. J Eur Acad Dermatol Venereol 29: 353-360.
- Van de Kerkhof P et al (2017) Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3. J Eur Acad Dermatol Venereol 31: 477-482.
- Williamson L et al (2004) Extended report: nail disease in psoriatic arthritis--clinically important, potentially treatable and often overlooked. Rheumatology (Oxford) 43: 790-794
- Wilson FC et al (2009) Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based studyArthritis Rheum 61: 233-239.
- You Z et al. (2020) Clinical parameters associated with severity of nail psoriasis and therapeutic efficacy. Eur J Dermatol 30: 362-371.
- Zisova L et al (2012) Onychomycosis in patients with psoriasis--a multicentre study Mycoses 55: 143-147.
Incoming links (14)
Immune related adverse events, cutaneous; Nail lichen planus ; Nail organ; Onychodystrophia psoriatica; Onycholysis psoriatica; Parakeratosis pustulosa; Blistering distal dactylitis; Fingertip pustulation; Hjorth-Sabouraud disease; Hjorth-Sabouraud Erkrnakung; ; Popp syndrome; Psoriasis of the nail; Psoriatic arthritis ; Psoriatic onychodystrophy; ... Show allOutgoing links (35)
Acitretin; Acrodermatitis continua suppurativa; Adalimumab; Anonychia (overview); Apremilast; Brodalumab; Ciclosporin A; Eczema nail; Etanercept; Guselkumab; ... Show allDisclaimer
Please ask your physician for a reliable diagnosis. This website is only meant as a reference.